Table of Content

1. Executive Summary

2. Disease Overview
2.1. Novel Coronavirus Etiology and Pathogenesis
2.2. Novel Human Coronavirus (ClOVID-19) Clinical Features-Signs and Symptoms

3. Disease Epidemiology and Epidemic Statistics for Major countries

4. Global Pipeline Analysis of COVID-19 Therapeutics and Vaccines
4.1 Global Pipeline Analysis, By Product Type
4.1.1 Small Molecules
4.1.2 Biologics
4.1.2.1 Blood & Plasma Derivatives
4.1.2.2 Monoclonal Antibodies
4.1.2.3 Vaccines
4.1.2.4 Others
4.2 Global Pipeline Analysis, By Phase of development
4.2.1 Preclinical Therapeutics & Vaccines
4.2.2 Clinical Studies
4.2.2.1 Clinical Phase I, II, III
4.3 Global Pipeline Analysis, By Treatment Mechanism & Route of Administration
4.3.1 Mechanism of Action
4.3.1.1 Viral Replication Inhibitors
4.3.1.2 Protease Inhibitors
4.3.1.3 Immunostimulants
4.3.1.4 Other Mechanism of Action
4.3.2 Route of Administration
4.3.2.1 Oral
4.3.2.2 Intravenous
4.3.2.3 Subcutaneous
4.3.2.4 Other Route of Administration
4.4 Global Pipeline Analysis, By Type of Sponsor
4.4.1 Pharma/Biotech Company
4.4.2 Academic Research/Institution
4.4.3 Others such as Government Organizations and CROs

5 Competitive Landscape for Late Stage Therapeutics and Vaccine
5.1 Company Overview
5.2 Product Description
5.3 Research and Development
5.3.1 Non-Clinical Studies
5.3.2 Clinical Studies
5.3.3 Highest/Late Stage Development Activities
5.4 Licensing and Collaboration Agreements
5.5 Milestones & Future Plans

6 Regulatory Framework for COVID-19 Therapeutics and Vaccines Marketing Approvals
6.1 Regulatory Framework in the USA
6.2 Regulatory Framework in EU and Other Countries

7 Recommendations & Conclusion